ADVISORY, March 2, 2010 (GLOBE NEWSWIRE) --
Peter Meldrum, President and CEO of Myriad Genetics, Inc. (MYGN), will visit NASDAQ MarketSite in Times Square and preside over the NASDAQ Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Wednesday, March 3, 2010 at 9:15 a.m. to 9:30 a.m. ET
The Opening Bell is available from 9:20 a.m. to 9:35 a.m. on Galaxy 19 C/15, downlink frequency 4000 vertical. The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
An audio transmission of the Opening Bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Myriad Genetics, Inc. (MYGN):
Myriad Genetics, Inc. is a leading molecular diagnostic company focused on the development and marketing of novel predictive medicine, personalized medicine and prognostic medicine products. The Company believes that the future of medicine lies in a shift from a treatment paradigm to a prevention paradigm. Myriad's strategy is to understand the role genes play in human disease and use that information to develop and commercialize products that assess a person's risk of developing disease later in life and guide treatment decisions based on an individual's genetic makeup and specific cause of disease.
The Company has launched seven commercial molecular diagnostic products, which are marketed through its own 300-person sales force. For the fiscal year ended June 30, 2009, revenues were $326.5 million, an increase of 47% over the prior fiscal year and net income was $84.6 million, an increase of 77% over the prior year. Myriad has approximately 1,000 employees focused on the development of novel molecular diagnostic products that save lives, improve the quality of life for patients, and save the healthcare system money.
On September 30, 2009, Myriad had $417 million in cash and marketable securities and had no debt or convertible debentures. The Company's securities are traded on the NASDAQ Global Select Market under the symbol "MYGN" and has approximately 96 million shares outstanding.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with over 3,700 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook(http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx).